Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of BLPH stock opened at $0.04 on Thursday. Bellerophon Therapeutics has a twelve month low of $0.03 and a twelve month high of $0.10. The stock has a fifty day simple moving average of $0.04 and a two-hundred day simple moving average of $0.05. The stock has a market capitalization of $440,388.00, a price-to-earnings ratio of -0.04 and a beta of 0.70.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.